Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Immunovant (IMVT) Return on Equity (2019 - 2026)

Immunovant filings provide 7 years of Return on Equity readings, the most recent being 0.01% for Q4 2025.

  • Quarterly Return on Equity changed 0.0% to 0.01% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.01% through Dec 2025, changed 0.0% year-over-year, with the annual reading at 0.01% for FY2025, 0.0% changed from the prior year.
  • Return on Equity hit 0.01% in Q4 2025 for Immunovant, up from 0.01% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.0% in Q4 2021 and bottomed at 0.01% in Q4 2024.
  • Average Return on Equity over 5 years is 0.01%, with a median of 0.01% recorded in 2023.
  • The largest annual shift saw Return on Equity changed 0bps in 2021 before it dropped -1bps in 2023.
  • Immunovant's Return on Equity stood at 0.0% in 2021, then crashed by -85bps to 0.0% in 2022, then dropped by -7bps to 0.01% in 2023, then tumbled by -83bps to 0.01% in 2024, then skyrocketed by 35bps to 0.01% in 2025.
  • Per Business Quant, the three most recent readings for IMVT's Return on Equity are 0.01% (Q4 2025), 0.01% (Q3 2025), and 0.01% (Q2 2025).